Hilton Santa Fe Historic Plaza Hotel Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2010



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Antibiotics and Resistance: Challenges and Solutions (B3)


Organizer(s) Gerry Wright, Deborah Hung and Stewart L. Fisher
February 14—19, 2010
Hilton Santa Fe Historic Plaza Hotel • Santa Fe, New Mexico USA
Abstract Deadline: Oct 14, 2009
Late Abstract Deadline: Nov 13, 2009
Scholarship Deadline: Oct 14, 2009
Early Registration Deadline: Dec 14, 2009

Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation

Summary of Meeting:
In the face of a growing crisis in antibiotic resistance and the emergence of new bacterial pathogens, there is a pressing clinical need for new antibiotics. Paradoxically, this call for new drugs comes at a time when investment in antibiotic development in the pharmaceutical industry is at historically low levels. Despite the promise of the genomic revolution to inform drug development and innovations in drug discovery and the fundamental biology that underpins it, modern control of infectious disease with antibiotics is perilously fragile. This meeting brings together researchers from medicine, academe and industry and from across scientific disciplines to discuss the challenges of antibiotic development in the 21st Century. What is the scope of the problem? What are possible solutions? What are the imperatives for the short and long term and is the traditional antibiotic paradigm in need of an overhaul? These questions will be the focus of the meeting that will help to define the problems and solutions in antibiotic development.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, FEBRUARY 14

15:00—19:30
Registration

Promenade
18:30—19:30
Refreshments

Promenade
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Gerry D. Wright, McMaster University, Canada

Patrice Courvalin, Institut Pasteur, France
Evolution and Dissemination of Antibiotic Resistance: The Glycopeptide Model the Van Saga


MONDAY, FEBRUARY 15

07:00—08:00
Breakfast

Chamisa
08:00—11:00
The Problem of Antibiotic Resistance and the Need for New Drugs
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Julian E. Davies, University of British Columbia, Canada

Donald E. Low, Mount Sinai Hospital, Canada
Bacterial Pathogens in the Hospital and Community: The need for New Antibiotics

Valerie Mizrahi, University of Cape Town, South Africa
New Tools for Tuberculosis Drug Discovery: Development of Novel Screening Strains of Mycobacterium tuberculosis and Application in Target-Based Approaches

Michael G. Surette, University of Calgary, Canada
The Clinical Challenge and Opportunities of Microbial Communities

Gerry D. Wright, McMaster University, Canada
Antibiotic Resistance: Where Does it Come from and What Can We Do About it?

09:20—09:40
Coffee Break

Promenade
11:00
On Own for Lunch and Recreation

11:00—13:00
Poster Setup

Mesa C/Chamisa
13:00—22:00
Poster Viewing

Mesa C/Chamisa
16:30—17:00
Coffee Available

Promenade
17:00—19:00
Success and Barriers in Modern Antibacterial Drug Discovery
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Stewart L. Fisher, C4 Therapeutics, Inc, USA

Julian E. Davies, University of British Columbia, Canada
Where will New Antibiotics Come From?

Mike Barbachyn, AstraZeneca Pharmaceuticals LP, USA
The Natural History of the Oxazolidinones

Patricia Bradford, Novartis Institutes for BioMedical Research, USA
Difficulties and Success in Bringing the 3rd Generation Tetracyclines to Market: The Story of Tigecycline

19:00—20:00
Social Hour with Lite Bites

Chamisa
19:30—22:00
Poster Session 1

Mesa C/Chamisa

TUESDAY, FEBRUARY 16

07:00—08:00
Breakfast

Chamisa
08:00—11:00
Mining Known Pathways as Targets for New Antibiotics
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Deborah Hung, Broad Institute, USA

Stewart L. Fisher, C4 Therapeutics, Inc, USA
DNA Replication: Challenges and Opportunities

Jennifer Campbell, Harvard Medical School, USA
Small Molecule Inhibitors of Wall Tecoic Acid Biosynthesis and their Effects on Staphylococcus aureus

Peter J. Tonge, Stony Brook University, USA
Slow Onset Inhibitors of Bacterial Fatty Acid Biosynthesis:Slow Onset Inhibition, Residence Time and in Vivo Activity

Thomas A. Steitz, HHMI/Yale University, USA
From the Structures of Ribosome-Antibiotic Complexes to New Antibiotics

Ronald W. Woodard, University of Michigan, USA
Short Talk: HTS Assay Developments in the KDO Biosynthesis Pathway

09:20—09:40
Coffee Break

Promenade
11:00
On Own for Lunch and Recreation

11:00—13:00
Poster Setup

Mesa C/Chamisa
13:00—22:00
Poster Viewing

Mesa C/Chamisa
16:30—17:00
Coffee Available

Promenade
17:00—19:00
New Molecules for New (and Old) Challenges
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Eric D. Brown, McMaster University, Canada

Christopher T. Walsh, Harvard Medical School, USA
Biosynthesis of Thiazolyl Peptide Antibiotics: a Bevi of Posttranslational Maturations

Mark J. Macielag, Johnson & Johnson Pharmaceutical Research & Development, USA
What Makes a Good Antibiotic? The Chemistry Perspective.

Chris Abell, University of Cambridge, UK
Application of Fragment-Based Approaches to the Discovery of New Agents Against Mycobacterium tuberculosis

Mervyn Bibb, John Innes Centre, UK
Short Talk: Actinomycete Lantibiotics: An Untapped Clinical Resource?

19:00—20:00
Social Hour with Lite Bites

Chamisa
19:30—22:00
Poster Session 2

Mesa C/Chamisa

WEDNESDAY, FEBRUARY 17

07:00—08:00
Breakfast

Chamisa
08:00—11:00
New Antibiotic Targets - Virulence and Quorum Sensing
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Michael G. Surette, University of Calgary, Canada

Robert E.W. Hancock, University of British Columbia, Canada
Modulation of Host Immunity as an Anti-Infective Strategy

Helen E. Blackwell, University of Wisconsin-Madison, USA
Expanding the Language of Bacterial Quorum Sensing using Synthetic Ligands

Vincent T. Lee, University of Maryland, USA
Are Type 3 Secretion Systems Good Targets for Antimicrobials?

Scott Hultgren, Washington University School of Medicine, USA
Bacterial Adhesion and Biofilm Formation - A Source of Alternate Antibiotic Targets

09:20—09:40
Coffee Break

Promenade
11:00
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Promenade
17:00—19:00
New Technology - Systems and Synthetic Biology
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Stewart L. Fisher, C4 Therapeutics, Inc, USA

Eric D. Brown, McMaster University, Canada
Chemical Genomics: Charting Chemical-Genetic Interactions in Bacteria

Frederick M. Ausubel, Massachusetts General Hospital, USA
Whole Organism Antibiotic Screening in C. elegans

* Deborah Hung, Broad Institute, USA
Antivirulence Therapy

19:00—20:00
Social Hour with Lite Bites

Chamisa

THURSDAY, FEBRUARY 18

07:00—08:00
Breakfast

Chamisa
08:00—11:00
New Technology - Real Time Diagnostics and Narrow vs. Broad Spectrum Agents
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Gerry D. Wright, McMaster University, Canada

Sylvie Garneau-Tsodikova, University of Michigan, USA
Turning an Aminoglycoside Resistance Problem into a Solution: New Approaches to Chemoenzymatic Synthesis of Antibiotics

Roy Kishony, Technion – Israel Institute of Technology, Israel
Inverting the Selective Advantage of Antibiotic Resistance

Jose Miguel Trevejo, Draper Laboratory/Beth Isreal Deaconess Boston, USA
Novel Sensors and Diagnostics for Rapid Identification of Microbial Resistance

Vincent A. Fischetti, Rockefeller University, USA
Using What Phage Have Learned to Kill Gram-Positive Bacteria

09:20—09:40
Coffee Break

Promenade
11:00
On Own for Lunch and Recreation

14:30—16:30
Workshop: Submitted Papers

Mesa A-B
* Stewart L. Fisher, C4 Therapeutics, Inc, USA

Bart Staker, Center for Infectious Disease Research, USA
Ligand Screening at the Seattle Structural Genomics Center for Infectious Disease (SSGCID)

Aileen Rubio, Spero Therapeutics, USA
Frequency and Distribution of Mutations in mprF in Daptomycin Nonsusceptible Staphylococcus aureus Clinical Isolates

Adriana Renzoni, University Hospital and Medical School of Geneva, Switzerland
Total Genome Sequencing and Complete Genetic Analysis of all SNP-Linked Phenotypes Reveals Novel Clues to the Emergence of Low Level Glycopeptide Intermediate Resistance in Staphylococcus aureus

Terence I. Moy, Cubist Pharmaceuticals, USA
High Rates of Resistance to Three Classes of RNA Polymerase Inhibitors in Staphylococcus aureus

Donald T. Moir, Microbiotix, Inc., USA
Characterization of a Stereo-Specific Class of Inhibitors of Type-Three Secretion

Dickon Alley, Anacor Pharmaceuticals, Inc., USA
Structure-Guided Discovery of ABX a 3-Aminomethyl Benzoxaborole: A First in Class Antibacterial for Gram-Negative Bacterial Infections

16:30—17:00
Coffee Available

Promenade
17:00—19:00
What about the Host?
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Deborah Hung, Broad Institute, USA

David A. Relman, Stanford University, USA
The Human Microbiome: Antibiotic Perturbation, Response, and Human Health

Dana Philpott, University of Toronto, Canada
Nod-like Receptors in Immunity, Inflamation and Disease

20:00—21:00
Social Hour with Lite Bites

Mesa Ballroom
20:00—23:00
Entertainment

Mesa Ballroom

FRIDAY, FEBRUARY 19

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI085733-01




We gratefully acknowledge additional support for this conference from:

Bill & Melinda Gates Foundation

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



AstraZeneca R&D


Johnson & Johnson Pharmaceutical Research & Development, L.L.C.


Novartis Institutes for BioMedical Research


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676